Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2019-04-26 Annual Report
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Annual Report 2018
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL REPORT 2018' and contains comprehensive sections typical of a full annual report, including a CEO's review, detailed clinical strategy, financial statements (consolidated and parent company), notes to the financial statements, and an auditor's report. It covers the full fiscal year 2018 and provides substantive financial and operational data, fitting the definition of a 10-K/Annual Report. FY 2018
2019-04-26 English
Oncopeptides kommer att ge ny vägledning om patientrekrytering i OCEAN-studien och en klinisk programuppdatering i en webbsändning klockan 10:00 (CET)
Earnings Release Classification · 1% confidence The document is a press release dated April 24, 2019, announcing that the company will provide an update on patient recruitment for the OCEAN Phase 3 study and a general clinical program update via a webcast/conference call. It details progress and delays in several clinical trials (OCEAN, HORIZON, ANCHOR, BRIDGE) and mentions upcoming regulatory discussions (FDA meeting). This content is a direct communication to investors and the public regarding ongoing operations, clinical progress, and future plans, rather than a formal regulatory filing like a 10-K, an official earnings release (ER), or a formal report (AR, IR). Since it is a detailed update on clinical strategy and progress presented to investors, the most fitting category is Investor Presentation (IP), even though it is delivered via a press release format announcing a webcast. It contains substantial operational and strategic detail typical of an investor update. FY 2019
2019-04-24 Swedish
Oncopeptides provides new guidance on the patient recruitment in the OCEAN study and a clinical program update in a webcast at 10:00 (CET)
Regulatory Filings Classification · 1% confidence The document is explicitly titled as a "Press release" dated April 24, 2019, from Oncopeptides AB. It announces an update on patient recruitment for the OCEAN study and provides a general clinical program update via a webcast/conference call. It details progress, delays, and future plans for several clinical trials (OCEAN, HORIZON, ANCHOR, BRIDGE). This content—a timely operational update disseminated via a press release, often preceding or accompanying a formal financial filing—is characteristic of an Earnings Release (ER) or a general operational update. Since it focuses on clinical trial progress and recruitment timelines rather than comprehensive financial statements (like a 10-K or IR), and it is an initial announcement of results/updates, the most appropriate classification is Earnings Release (ER). It is not a full transcript (CT), a formal annual report (10-K), or a specific regulatory filing like DIRS or DIV. It is an announcement of operational/clinical status, which often overlaps with ER content.
2019-04-24 English
ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled "ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)" (Annual General Meeting in Oncopeptides AB (publ)) and details the date, location, registration procedures, agenda items (including election of board members, auditors, and remuneration), and specific proposals related to incentive programs for board members. This content is characteristic of materials prepared for and presented at an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2019-04-16 Swedish
ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled "ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)" and details the notice, agenda, proposed resolutions, and procedures for shareholders to attend and vote at this meeting. Key elements include the date of the meeting (May 21, 2019), the required registration date (May 15, 2019), and a detailed agenda covering the election of the board, approval of financial statements, and remuneration proposals. This content directly corresponds to the purpose of an Annual General Meeting (AGM) notice and related materials. Therefore, the classification is AGM-R.
2019-04-16 English
Earnings Release 2018
Earnings Release Classification · 1% confidence The document is titled "Bokslutskommuniké 2018" (Year-End Report/Financial Statement Communication 2018) and contains a detailed financial overview for Q4 2018 and the full year 2018, including key figures like Net Sales, Net Income, and Earnings Per Share. It also includes management commentary on operations, clinical trials (OCEAN, HORIZON, ANCHOR), and future plans. This structure strongly indicates a comprehensive report covering a full fiscal year's performance, which aligns with the definition of an Annual Report (10-K). Although the title uses 'Bokslutskommuniké' (Year-End Communication), the depth and scope cover the full annual performance, making 10-K the most appropriate classification among the provided options for a comprehensive annual financial disclosure, rather than just an Earnings Release (ER) or Interim Report (IR). The document length is substantial (over 60k characters), confirming it is the full report, not just an announcement of one. Q4 2018
2019-02-22 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.